Annexon Biosciences
Annexon Biosciences raises $125M Series D at $750M valuation
Annexon Biosciences: Series D Funding Round
Annexon Biosciences has successfully raised $125M in Series D funding, reaching a valuation of $750M.
Company Overview
Classical complement pathway inhibitors
Funding Details
The Series D round was led by GV, with participation from Alta Partners, Omega Funds, Cowen Healthcare Investments, Redmile Group.
Company Information
- Headquarters: 180 Kimball Way, South San Francisco, CA 94080
- Founded: 2011
- Employees: 150+
- Category: Biotech
Investment
Annexon Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- GV: Verified investor in Series D
- Alta Partners: Verified investor in Series D
- Omega Funds: Verified investor in Series D
- Cowen Healthcare Investments: Verified investor in Series D
- Redmile Group: Verified investor in Series D
Company Info
Investors (5)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free